Nplate (romiplostim) is a thrombopoietin receptor agonist indicated for treating thrombocytopenia in ITP patients with insufficient response to conventional therapies and for increasing survival in patients exposed to myelosuppressive radiation doses, with its therapeutic effect primarily achieved through stimulation of platelet production.

Clinical Efficacy of Nplate in Thrombocytopenia Management

Romiplostim functions as a thrombopoietin receptor agonist that stimulates megakaryocytopoiesis to increase platelet production. The therapeutic goal is to achieve and maintain platelet counts ≥50×10^9/L to reduce bleeding risk, with median effective doses of 2-3 mcg/kg in responsive adult patients. Nplate is specifically indicated for:

Adult ITP patients with inadequate response to corticosteroids, immunoglobulins, or splenectomy

Pediatric ITP patients ≥1 year with persistent disease (≥6 months) unresponsive to standard therapies

Radiation-induced myelosuppression (Hematopoietic Syndrome of Acute Radiation Syndrome)